US Medical Innovations (USMI) and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) have announced the launch of the new Canady Robotic AI Surgical System.

It is claimed to be the world’s first artificial intelligence (AI) robotic system that generates cold atmospheric plasma (CAP), and a three-dimensional non-contact bioelectric pulse electromagnetic field.

CAP precisely targets and eliminates microscopic tumour cells during surgery while preserving the health of non-cancerous surrounding tissue.

The new system features an ORLI speech recognition Canady electrosurgical generator, a controller for CAP devices and robotic-assisted end effectors that can be used in open, thoracoscopic, laparoscopic, endoscopic and mini-invasive surgical procedures.

It also offers the surgeon ten degrees of freedom, AI-powered software programmes, 3D navigational-guided surgical planning and speech activation of the robotic movements.

Furthermore, the system provides advanced contour tracking of the CAP beam and pre-programmed CAP dosimetry data to selectively target 32 cancer cell types in a compact mobile design.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

USMI CEO and surgical oncologist Jerome Canady said: “This technology will transform the landscape of the OR. ORLI is a user-friendly system controlling the entire integrated SMART operating room. The platform will serve as a Siri, Alexa and Google Home for the operating room.

“Data collected from our recent FDA Phase I Clinical Trial on stage four cancer patients combined with ten years of in-vitro translational molecular research data have been imported into the Canady robotic AI surgical system.”